Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Capital Expenditures (2016 - 2025)

Standard Biotools (LAB) has disclosed Capital Expenditures for 16 consecutive years, with -$48000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 105.13% to -$48000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $7.6 million, a 645.8% increase, with the full-year FY2024 number at $8.4 million, up 195.13% from a year prior.
  • Capital Expenditures was -$48000.0 for Q3 2025 at Standard Biotools, up from -$4.9 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $7.4 million in Q4 2024 to a low of -$4.9 million in Q2 2025.
  • A 5-year average of $1.5 million and a median of $905000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 9412.82% in 2024, then tumbled 523.69% in 2025.
  • Standard Biotools' Capital Expenditures stood at $500000.0 in 2021, then skyrocketed by 51.0% to $755000.0 in 2022, then tumbled by 89.67% to $78000.0 in 2023, then soared by 9412.82% to $7.4 million in 2024, then plummeted by 100.65% to -$48000.0 in 2025.
  • Per Business Quant, the three most recent readings for LAB's Capital Expenditures are -$48000.0 (Q3 2025), -$4.9 million (Q2 2025), and $5.1 million (Q1 2025).